News and commentary from the world of neurology and neuroscience
— News and commentary from the world of neurology and neuroscience
by Judy George, Deputy Managing Editor, MedPage Today
August 11, 2026
• 2 min read
Shanghai-based biotech company HuidaGene Therapeutics disclosed the death of a child 1 year ago in a trial of an investigational gene-editing therapy for Duchenne muscular dystrophy.
With a second delayed report of a child's death in China, criticism is rising of a looser form of clinical trial. One expert:…
A patient with Duchenne muscular dystrophy died after receiving a gene-editing therapy in China, sparking new concerns about…
Two undisclosed deaths in Chinese gene-editing trials renew concerns about trial oversight, safety reporting, and transparency as…
Death of youngster following experimental gene therapy only made public after journalists investigated
A 6-year-old girl who received an experimental gene editing treatment died seven days into a clinical trial in Shanghai...
A Chinese university is looking into reports that a gene-editing trial caused the death of a six-year-old girl, which was not…
Patient dies in China biotech company’s gene editing trial
Two Deaths In China Reopen Gene Therapy Debates
Muere un segundo niño tratado en China con una terapia de edición genética
Two FDA approvals — a new drug and a new vaccine
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
